• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Silver acetate for smoking cessation.

作者信息

Lancaster T, Stead L F

机构信息

ICRF General Practice Research Group, Division of Public Health and Primary Health Care, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF.

出版信息

Cochrane Database Syst Rev. 2000(2):CD000191. doi: 10.1002/14651858.CD000191.

DOI:10.1002/14651858.CD000191
PMID:10796505
Abstract

BACKGROUND

Silver acetate produces an unpleasant taste when combined with cigarettes, thereby producing an aversive stimulus. It has been marketed in various forms with the aim of extinguishing the urge to smoke, by pairing the urge with an unpleasant stimulus.

OBJECTIVES

The aim of this review was to determine the effectiveness of silver acetate products (gum, lozenge, spray) in promoting smoking cessation.

SEARCH STRATEGY

We searched the Cochrane Tobacco Addiction Group trials register.

SELECTION CRITERIA

We included randomised trials of silver acetate for smoking cessation with reports of smoking status at least six months after the beginning of treatment.

DATA COLLECTION AND ANALYSIS

We extracted data in duplicate on the type of subjects, the dose and form of silver acetate, the outcome measures, method of randomisation, and completeness of follow-up. The main outcome measure was biochemically validated abstinence from smoking after at least six months follow-up in patients smoking at baseline. Subjects lost to follow-up were counted as continuing smokers. Where appropriate, we performed meta-analysis using a fixed effects model.

MAIN RESULTS

Two studies provided long-term follow-up data on patients randomised to silver acetate or placebo. In one of these studies, there was a third arm, randomised to 2mg nicotine gum. The combined odds ratio for quitting for silver acetate vs placebo was 1.05 (95% confidence interval 0.63 to 1.73).

REVIEWER'S CONCLUSIONS: Existing trials show little evidence for a specific effect of silver acetate in promoting smoking cessation. The confidence intervals for the ratio are quite wide. However, the upper limit of the confidence intervals for a positive effect equates to an absolute increase in the smoking cessation rate of about 4%. Any effect of this agent is therefore likely to be smaller than nicotine replacement therapy. The lack of effect of silver acetate may reflect poor compliance with a treatment whose rationale is to create an unpleasant stimulus.

摘要

相似文献

1
Silver acetate for smoking cessation.
Cochrane Database Syst Rev. 2000(2):CD000191. doi: 10.1002/14651858.CD000191.
2
Nicotine replacement therapy for smoking cessation.用于戒烟的尼古丁替代疗法。
Cochrane Database Syst Rev. 2000(3):CD000146. doi: 10.1002/14651858.CD000146.
3
Nicotine replacement therapy for smoking cessation.用于戒烟的尼古丁替代疗法。
Cochrane Database Syst Rev. 2002(4):CD000146. doi: 10.1002/14651858.CD000146.
4
Silver acetate for smoking cessation.用于戒烟的醋酸银。
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD000191. doi: 10.1002/14651858.CD000191.pub2.
5
Nicotine replacement therapy for smoking cessation.用于戒烟的尼古丁替代疗法。
Cochrane Database Syst Rev. 2000(2):CD000146. doi: 10.1002/14651858.CD000146.
6
Nicotine replacement therapy for smoking cessation.用于戒烟的尼古丁替代疗法。
Cochrane Database Syst Rev. 2001(3):CD000146. doi: 10.1002/14651858.CD000146.
7
Nicotine replacement therapy for smoking cessation.用于戒烟的尼古丁替代疗法。
Cochrane Database Syst Rev. 2004(3):CD000146. doi: 10.1002/14651858.CD000146.pub2.
8
Nicotine replacement therapy versus control for smoking cessation.尼古丁替代疗法与对照用于戒烟
Cochrane Database Syst Rev. 2018 May 31;5(5):CD000146. doi: 10.1002/14651858.CD000146.pub5.
9
Self-help interventions for smoking cessation.戒烟的自助干预措施。
Cochrane Database Syst Rev. 2002(3):CD001118. doi: 10.1002/14651858.CD001118.
10
Group behaviour therapy programmes for smoking cessation.用于戒烟的团体行为治疗方案。
Cochrane Database Syst Rev. 2002(3):CD001007. doi: 10.1002/14651858.CD001007.

引用本文的文献

1
Innovations in Chewable Formulations: The Novelty and Applications of 3D Printing in Drug Product Design.咀嚼片剂型的创新:3D打印在药品设计中的新颖性及应用
Pharmaceutics. 2022 Aug 18;14(8):1732. doi: 10.3390/pharmaceutics14081732.
2
Metal-Enhanced Fluorescence (MEF) Due to Silver Colloids on a Planar Surface: Potential Applications of Indocyanine Green to in Vivo Imaging.平面表面上银胶体导致的金属增强荧光(MEF):吲哚菁绿在体内成像中的潜在应用。
J Phys Chem A. 2003 May 1;107(18):3443-3449. doi: 10.1021/jp022040q. Epub 2003 Mar 20.
3
Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
戒烟的药物干预:综述与网状Meta分析
Cochrane Database Syst Rev. 2013 May 31;2013(5):CD009329. doi: 10.1002/14651858.CD009329.pub2.
4
Silver acetate for smoking cessation.用于戒烟的醋酸银。
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD000191. doi: 10.1002/14651858.CD000191.pub2.
5
[Guidelines for smoking cessation - update 2010].[戒烟指南 - 2010年更新版]
Wien Klin Wochenschr. 2011 May;123(9-10):299-315. doi: 10.1007/s00508-011-1571-x. Epub 2011 May 16.
6
Interventions for promoting smoking cessation during pregnancy.孕期促进戒烟的干预措施。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD001055. doi: 10.1002/14651858.CD001055.pub3.
7
An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts.一种针对戒烟的药物治疗定制算法:来自国际专家德尔菲小组的结果。
Tob Control. 2009 Feb;18(1):34-42. doi: 10.1136/tc.2008.025635. Epub 2008 Oct 9.
8
A review of smoking cessation interventions.戒烟干预措施综述
MedGenMed. 2005 Jun 7;7(2):24.
9
Aversive smoking for smoking cessation.厌恶疗法戒烟。
Cochrane Database Syst Rev. 2004;2001(3):CD000546. doi: 10.1002/14651858.CD000546.pub2.
10
Metal-enhanced emission from indocyanine green: a new approach to in vivo imaging.吲哚菁绿的金属增强发射:一种体内成像的新方法。
J Biomed Opt. 2003 Jul;8(3):472-8. doi: 10.1117/1.1578643.